Last reviewed · How we verify
Ceepryn (CETYLPYRIDINIUM)
Ceepryn (generic name: CETYLPYRIDINIUM) is a cetylpyridinium drug. It is currently FDA-approved for Local anesthesia, Mouth Irritation, Suppression of the Gag Reflex.
At a glance
| Generic name | CETYLPYRIDINIUM |
|---|---|
| Drug class | cetylpyridinium |
| Target | Caspase-2 |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Approved indications
- Local anesthesia
- Mouth Irritation
- Suppression of the Gag Reflex
Common side effects
- Gastrointestinal toxicity
- Pulmonary toxicity
- Joint injury
- Neoplasm malignant
- C-reactive protein abnormal
- Hepatotoxicity
- Therapy non-responder
- Joint stiffness
- Musculoskeletal pain
- Musculoskeletal stiffness
- Therapeutic product effect incomplete
- Treatment failure
Key clinical trials
- Antiplaque Efficacy and Patient Reported Outcome of Chlorohexidine, Cetylpyridinium Chloride, and Essential Oil Mouthwashes in Orthodontic Patients (NA)
- Microbiological Effect of 0.12% Chlorhexidine Digluconate and 0.05% Cetylpyridinium Chloride vs Probiotics (Lactobacillus Reuteri Prodentis) on Porphyromonas Gingivalis. (PHASE4)
- Clinical Research Study to Assess the Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis. (PHASE3)
- Effect of Mouthwash in Reducing the Symptoms Associated With Flu and Cold Viruses (PHASE3)
- A Study to Evaluate the Efficacy of a Stannous Fluoride Toothpaste With a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation (NA)
- Theravex Oral and Theravex Tissue Care Plus in the Healing Process of Mucogingival Surgery (NA)
- Efficacy of a Stannous Fluoride Toothpaste, Cetylpyridinium Chloride Mouthwash, and Battery Toothbrush Regimen in Reducing Established Dental Plaque and Gingivitis. (PHASE3)
- Oral Rinse to Reduced Expelled Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) During COVID-19 Infection (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ceepryn CI brief — competitive landscape report
- Ceepryn updates RSS · CI watch RSS
Frequently asked questions about Ceepryn
What is Ceepryn?
Ceepryn (CETYLPYRIDINIUM) is a cetylpyridinium drug, indicated for Local anesthesia, Mouth Irritation, Suppression of the Gag Reflex.
What is Ceepryn used for?
Ceepryn is indicated for Local anesthesia, Mouth Irritation, Suppression of the Gag Reflex.
What is the generic name of Ceepryn?
CETYLPYRIDINIUM is the generic (nonproprietary) name of Ceepryn.
What drug class is Ceepryn in?
Ceepryn belongs to the cetylpyridinium class. See all cetylpyridinium drugs at /class/cetylpyridinium.
What development phase is Ceepryn in?
Ceepryn is FDA-approved (marketed).
What are the side effects of Ceepryn?
Common side effects of Ceepryn include Gastrointestinal toxicity, Pulmonary toxicity, Joint injury, Neoplasm malignant, C-reactive protein abnormal, Hepatotoxicity.
What does Ceepryn target?
Ceepryn targets Caspase-2 and is a cetylpyridinium.
Related
- Drug class: All cetylpyridinium drugs
- Target: All drugs targeting Caspase-2
- Therapeutic area: All drugs in Pain
- Indication: Drugs for Local anesthesia
- Indication: Drugs for Mouth Irritation
- Indication: Drugs for Suppression of the Gag Reflex
- Compare: Ceepryn vs similar drugs
- Pricing: Ceepryn cost, discount & access